Ductal Adenocarcinoma, Including Variants
Comprises 85-90% of all pancreatic neoplasms
Clinical Issues
•
Most cases unresectable at presentation
•
Nonspecific symptoms often mean delay in diagnosis
Macroscopic
•
Majority in head of pancreas
•
Poorly defined, firm mass with intense fibrotic reaction
Carcinoma may be difficult to distinguish from background pancreatitis
Microscopic
•
Small, haphazardly infiltrating glands embedded in dense desmoplastic stroma
•
Perineural and angiolymphatic invasion and associated chronic pancreatitis are very common
•
Histologic patterns: Foamy gland pattern, large duct pattern
Colloid carcinoma, adenosquamous, clear cell, signet ring, medullary, hepatoid, undifferentiated, carcinomas with mixed differentiation
•
Immunohistochemistry
Cytokeratins 7, 8, 18, 19
CEA, CA19-9, CA125, B72.3
MUC1, MUC4, MUC5AC, and MUC6 (25%)
TERMINOLOGY
Abbreviations
•
Pancreatic ductal adenocarcinoma (PDAC)
Synonyms
•
Pancreatic adenocarcinoma
•
Duct cell adenocarcinoma
Definitions
•
Malignant epithelial neoplasm arising in pancreatic ductal system
85-90% of all pancreatic neoplasms
•
Predominantly glandular differentiation
ETIOLOGY/PATHOGENESIS
Hereditary Risk Factors
•
Family history of pancreatic cancer
•
Hereditary pancreatitis
•
Familial atypical multiple mole melanoma syndrome
•
BRCA2 and
BRCA1 mutations
Medical Risk Factors
•
Previous cholecystectomy or partial gastrectomy
Environmental and Occupational Risk Factors
•
Cigarette smoking approximately doubles risk
•
Diet high in meat, fat, nitrates, and pork products
•
Chemicals (solvents, DDT, gasoline)
•
Occupational (coal gas workers, metal working, hide tanning, dry cleaning)
Precursor Lesions
•
Pancreatic intraepithelial neoplasia
Molecular Classification
•
4 groups based on genomic analysis
Squamous, pancreas progenitor, immunogenic, aberrantly differentiated endocrine exocrine
Hold promise for future therapies
CLINICAL ISSUES
Epidemiology
•
Age
Peak incidence in 7th and 8th decades of life
–
Majority of cases occur between age 60-80
•
Sex
M:F = 1.3:1
•
Ethnicity
More common in Maoris, native Hawaiians, and African Americans
Presentation
•
Nonspecific symptoms may delay diagnosis
Epigastric pain, weight loss
Biliary obstruction, painless jaundice
•
Disease associations
Trousseau syndrome (migratory thrombophlebitis)
Diabetes mellitus
Sister Mary Joseph sign (palpable periumbilical nodules)
Courvoisier sign (distended, palpable gallbladder)
Treatment
•
Resection
Only 10-20% of cases resectable at diagnosis
•
Chemotherapy before resection, after resection, or both
Common regimens: FOLFIRINOX (folate, 5-fluorouracil, irinotecan, oxaliplatin), gemcitabine/nab-paclitaxel
Neoadjuvant therapy associated with higher survival
Prognosis
•
Dismal; 5-year survival < 5%
IMAGING
General Features
•
CT scan commonly used for diagnosis and staging
•
MR angiography can help to determine resectability
•
Endoscopic US with biopsy reliable for diagnosis and staging
•
ERCP/MRCP helps visualize ductal system
MACROSCOPIC
General Features
Get Clinical Tree app for offline access